CBFA2T3

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Monday, March 25, 2024
CBFA2T3, Endometrial cancer, NSCLC, ASH, AML, International, Part, Patient, SAN, STRO, Acute myeloid leukemia, Cancer, Spacecraft, Lung cancer, RAM, PROC, Investment, Phenotype, Society, ADC, Hematology, Nursing

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2023, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • “The year 2023 was pivotal for Sutro, with the initiation of REFRαME-O1, our registration-directed study of luvelta for platinum-resistant ovarian cancer (PROC) patients, further validating our next-generation ADC capabilities.
  • The registration-directed trial, REFRαME-O1, for treatment of PROC is enrolling, with an anticipated ~140 sites in ~20 countries to be opened by the end of 2024.
  • Upon exercising the option, Vaxcyte paid Sutro $50 million and is obligated to pay Sutro an additional $25 million within six months.
  • Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Retrieved on: 
Thursday, January 4, 2024
CBFA2T3, Lung cancer, ESMO, Division, Woman, IND, Ovarian cancer, Drug discovery, PD-1, PROC, Spacecraft, Neutropenia, SAN, Gynecologic Oncology (journal), RAM, Endometrial cancer, Q&A, STRO, University, ASH, Bevacizumab, Patient, Phenotype, Acute myeloid leukemia, Safety, Webcast, ADC, NSCLC, AML, Birth control

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting an investor webcast today highlighting the significant potential of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC. The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRα-expressing cancers, including platinum-resistant ovarian cancer (PROC), endometrial cancer, CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC).

Key Points: 
  • “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile.
  • We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRα expression, which could double the current eligible patient population relative to the FolRα-targeting ADC on the market.
  • Sutro management and Dr. Monk will participate in a Q&A session at the end of the presentation.

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Retrieved on: 
Thursday, December 14, 2023
CBFA2T3, Lung cancer, Ovarian cancer, Spacecraft, PROC, SAN, RAM, Endometrial cancer, Q&A, STRO, Cancer, Webcast, Patient, Phenotype, Acute myeloid leukemia, ADC

The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.

Key Points: 
  • The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.
  • ET featuring presentations by members of Sutro’s senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
  • To access the live audio webcast on Thursday, January 4, at 1:30 p.m. PT / 4:30 p.m.
  • ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
    An archived replay of the webcast will be available on the Company’s website following the live presentation.

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Thursday, March 30, 2023
Bevacizumab, ASH, Neoplasm, DOR, Acute megakaryoblastic leukemia, Sutro, Investment, Patient, MM, Ageing, Spacecraft, CBFA2T3, SVP, Clinical, Bone marrow, Business development, Hematology, Multiple myeloma, Drug discovery, Research, Lung cancer, TPS, Corporation, ADC, FDA, IND, Exercise, DNA, Interim, Index, International, Lymphoid leukemia, ReFrame, NSCLC, EMD, PFS, Quality assurance, MTD, Depreciation, Merck Serono, Ovarian cancer, ORR, Astellas Pharma, IADC, NHL, AML, Endometrial cancer, STRO, BMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, BCMA, Breast cancer, ROR1, Cryptocurrency, Pharmaceutical industry, Management, Birth control, Vaccine, Merck, Tasly

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • The safety profile is generally consistent with prior data; asymptomatic neutropenia was the primary adverse event and no new safety signals were observed.
  • Additional Pipeline Programs: A Sutro Research Forum, held in 2022, highlighted STRO-003 and Sutro’s emerging research portfolio.
  • Sutro bolstered the Senior Management Team with the promotion of Brunilda Shtylla to Chief Business Officer, who leads Business Development.
  • Total operating expenses for the year ended December 31, 2022 were $196.7 million, as compared to $160.4 million for the same period in 2021.